呼吸印迹分析和仿生传感器技术检测肺癌

2023-04-02 10:03

目前，对肺癌的评估和筛查是基于血液检测、计算机断层扫描和正电子发射断层扫描的组合。

SCI 1 April 2023

Breathprinting analysis and biomimetic sensor technology to detect lung cancer

(IF: The Journal of Thoracic and Cardiovascular Surgery, 6.439)

Vanstraelen S, Jones DR, Rocco G, Breathprinting analysis and biomimetic sensor technology to detect lung cancer, The Journal of Thoracic and Cardiovascular Surgery (2023)

Gaetano Rocco, MD, FACS, FRCS(Ed), FEBTS

Thoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center

1275 York Avenue

New York, NY 10060

roccog@mskcc.org

212-639-3478

At present, evaluation and screening for lung cancer are based on a combination of blood tests, computed tomography, and positron emission tomography. In early-stage tumors, imaging still yields high false-positive rates; therefore, definitive diagnosis relies on pathologic confirmation (i.e., biopsy and surgery), which can result in complications. Moreover, up to 11% of resected small pulmonary nodules without preoperative pathologic confirmation are ultimately benign. Therefore, to increase diagnostic accuracy and ultimately change the fate of these patients, researchers and clinicians have strived to implement innovative and minimally invasive approaches to identify diagnostic biomarkers of lung cancer that are detectable in blood, urine, or exhaled breath.

目前，对肺癌的评估和筛查是基于血液检测、计算机断层扫描和正电子发射断层扫描的组合。在早期肿瘤中，成像仍然可能产生较高的假阳性率；因此，最终诊断依赖于病理学确认（即活检和手术），然而这可能会导致并发症。此外，高达11%的未经术前病理证实的，切除的肺小结节最终病理被证实是良性的。因此，为了提高诊断准确性并最终改变这些患者的命运，研究人员和临床医生一直在努力实施创新的微创方法，以确定可在血液、尿液或呼出气体中检测到肺癌诊断生物标志物。